Full-Time
Director - Toxicology
Non-Clinical Drug Safety
Posted on 10/4/2025
Enveda Biosciences
201-500 employees
Biotech drug discovery via high-throughput ML
Compensation Overview
$215k - $230k/yr
Boulder, CO, USA
Remote
 Medical, Clinical & Veterinary (1) |
|---|
- PhD, or similar advanced degree with DABT
- 10+ years executing non-clinical strategies and leading toxicology programs
- Demonstrated success in timely IND and Regulatory submissions, submission of the IND-enabling package (safety pharmacology and toxicology reports and SEND data)
- Good understanding of the FDA and ICH Regulatory Guidelines in Toxicology
- Demonstrated success in working with CROs for non-clinical studies in Safety Pharmacology (SP) and Toxicology in accordance with Good Laboratory Practices (GLP)
- Conduct of phase-appropriate IND-enabling and nonclinical toxicology studies
- Experience in Juvenile/Reprotox and Subchronic/Chronic studies, dermatology, inhalation or neuro programs, related toxicology studies, Carcinogenicity studies a plus
- Interpret and summarize toxicology findings and Author/review of Module 2 summaries: Module 2.6.2/2.6.3 Secondary and Safety Pharmacology, Module 2.6.6/2.6.7 Toxicology, Module 2.4 Nonclinical Overview (NCO), Investigator’s Brochure (Nonclinical sections)
- Ability to lead and manage simultaneous IND-enabling Programs with quality and integrity
- Ability to work independently and collaborate in a cross-functional Drug Development Team
- IND-enabling activities including pre-clinical safety pharmacology (SP) and toxicology and further nonclinical development for drug approval
- Design and implementation of nonclinical development stage strategies for specific programs for small molecules
- Provide toxicology expertise to the discovery and portfolio programs
- Provide sound guidance to teams on dose selection and safety studies and risk assessments for discovery and developmental programs
Enveda Biosciences focuses on drug discovery by tapping into the natural world’s largely uncharted chemical space. It uses a proprietary platform to run high-throughput experiments that generate a comprehensive dataset of small molecules, analyzing chemical structure, biological activity, and organ distribution to rapidly identify drug leads. The company integrates machine learning, metabolomics, and robotics to accelerate discovery and move faster from natural compounds to potential medicines. Its main differentiator is a data-enabled, platform-driven approach that combines advanced analytics with automated experimentation to explore natural products at scale, enabling partnerships and licensing deals with healthcare and pharmaceutical companies. Enveda’s goal is to expand the known chemical space of nature and provide a steady pipeline of promising drug candidates to its clients.
Company Size
201-500
Company Stage
Series D
Total Funding
$534.8M
Headquarters
Boulder, Colorado
Founded
2019
Simplify's Take
What believers are saying
- Raised $150M Series D in 2025, reaching $517M total funding and unicorn status.
- Three clinical-stage assets in eczema, asthma, obesity with $20B sales potential.
- Appointed Christopher Porter SVP Clinical and Jason Kim CFO in 2024-2025.
What critics are saying
- ENV-294 Phase 1b fails efficacy in atopic dermatitis by mid-2026, burns cash.
- Insilico’s INS018_055 Phase 2 success steals Sanofi partnerships in 12 months.
- FDA holds obesity IND in Q2 2026 over metabolite toxicity in preclinical data.
What makes Enveda Biosciences unique
- Enveda decodes natural chemical biodiversity using AI, mass spectrometry, and robotics.
- Platform discovers drugs 4x faster at 1/10th cost versus traditional pharma.
- Translates medicinal plant molecules into therapies for inflammation, fibrosis, pain.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Traditional or Roth 401k matching of 4% (100% of your contributions up to 4% of your annual compensation)
Medical, dental and vision insurance. 100% coverage of employee premiums and 33% coverage of dependents
Unlimited paid time off
Flexible work hours and paid parental leave
Company-wide weeklong break to recharge in addition to 8 observed holidays
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↓ -3%Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.
Enveda Biosciences, a Colorado biotech, has secured an additional $150 million for its I&I drug and a wide-ranging pipeline of preclinical assets. The company has grown from an initial $50k "pre, pre-seed" investment to $517 million in total funding, achieving unicorn status.
Enveda Biosciences raised $150 million in Series D funding, doubling its venture capital intake this year. The round was led by Premji Invest and included investors like Kinnevik and Lux Capital. Enveda has begun Phase 1b trials for its lead drug candidate in atopic dermatitis and plans to enter more drugs into human trials soon. The company aims to file investigational new drug applications for other programs over the next year.
AI is helping Corteva Agriscience dramatically accelerate the development of new crop protection products by modeling proteins and molecules with “unprecedented speed and accuracy,” an exec told a congressional subcommittee this morning. Speaking at a House Environment Subcommittee hearing on innovations in agrichemicals, Brian Lutz, PhD, VP agricultural solutions at Corteva, said AI had “revolutionized discovery by allowing us to trade randomness and chance for prediction, specificity and design.”. Predicting the structure of proteins in seconds
Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M